SAŽETAK

Novija saznanja o ulozi inflamacije u nastanku astme su otvorila nove mogućnosti u terapijskom pristupu ovoj bolesti. Značaj klasične terapije je neosporan, ali se sve više nameće potreba za uvođenjem novih lekova. Antileukotrijenski lekovi su visoko specifični i selektivni sa izrazito malo neželjenih efekata i vrlo 'popularnom', peroralnom administracijom. Ostaje međutim, otvoreno pitanje odnosa efikasnosti-cene, a time i pristupačnost ovih lekova široj populaciji astma pacijenata.

Ključne reči: leukotrijeni, antileukotrienski lekovi, astma

SUMMARY

The latest knowledge on the role of inflammation for the development of asthma has made it possible for the new therapeutic modalities of the treatment approach to this disease to be applied. The standard medicamentous treatment is doubtlessly still important, but a necessity of finding new drugs is becoming increasingly evident. Antileukotiene drugs are highly specific and selective, producing really few side-effects, having an easy and popular oral administration. However, there still remains one open question to be solved - it is the relationship between the drug efficacy and price, that is the problem of the drug's availability to a larger number of asthmatic patients.

Key words: leukotrienes, anti-leukotriene drugs, asthma